STX Shield Therapeutics

Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous

Hardman & Co Research
Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous

12-Aug-2022 / 11:45 GMT/BST


Hardman & Co Video | Analyst interview

Shield Therapeutics (STX): Upside potential is enormous

Shield Therapeutics (STX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews.

Despite launching a drug into the US market, Shield has performed really badly over

the past 12 months, Martin explains what happened, shares his thoughts on the considerable progress made, implications for the full year, why the share price is falling, investment capital and the investment opportunity.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late stage, hospital focused pharmaceuticals.

 

Listen to the interview :

If you are interested in meeting the company, you can register your interest

Download our latest report on STX,

To contact us:

Hardman & Co
1 Frederick’s Place

London

EC2R 8AE

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall



+44 (0)203 693 7075

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1419419  12-Aug-2022 

fncls.ssp?fn=show_t_gif&application_id=1419419&application_name=news&site_id=research_pool
EN
12/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shield Therapeutics

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 9 February 2026

* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: Versarien (VRS.L) left AIM. What’s baking in the oven? Market Movers:*** 14 January: GlobalData (DATA.L), the data, insight, a...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Monthly - February Edition

Hybridan Monthly, 3 February 2026 Market Comment: By Niall Pearson For a special February 2026 edition of Hybridan’s View from the Broker’s Desk, we are delighted to be joined by Laurence Hulse, founder of Onward Opportunities, a leading UK Small Cap Investment Trust. Laurence started his career at Gresham House in 2015, around the time of its inception, and worked on a number of outperforming equity products. Recently, Onward Opportunities reported a record year of net asset value growth in the...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 21 January 2026

21st January 2026 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: None What’s baking in the oven? IPOs:** 14th January...

Martin Hall
  • Martin Hall

Hardman & Co Healthcare Index: 2025 – Index rose, but another tough ye...

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025. While this sounds positive, it was below the strong performance of most major UK healthcare stocks and, in general, it underperformed its UK and peer benchmarks: FTSE 100 (+21.5%); FTSE All-Share (+19.8%); and the NASDAQ Biotech Index (NBI; +32.4%). Th...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 3 December 2025

3rd December 2025 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: Yes...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch